Increased PrEP Uptake in US Metropolitan Statistical Areas During 2012-2017 Associated With Significant Reduction in New HIV Diagnoses Rate

Source: 2019 IDWeek, the Co-morbidities and Adverse Drug Reactions Workshop, and the European AIDS Conference*
Download Slideset
IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
The contribution of PrEP to decline in HIV incidence was 2.1 times larger than treatment as prevention in an analysis considering both interventions.
Format: Microsoft PowerPoint (.ppt)
File Size: 164 KB
Released: October 29, 2019

Acknowledgements

Provided by USF Health
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

HIV self-testing and 6-month PrEP dispensing simplified PrEP delivery with no reduction in HIV testing or PrEP adherence, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Efficacy of doxycycline PEP for prevention of STIs in MSM and TGW in the DoxyPEP study, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 4, 2022

HPTN 084 updated safety and efficacy data on long-acting cabotegravir for HIV PrEP in cisgender women, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 3, 2022

Safety, efficacy, pharmacokinetics of LA cabotegravir for HIV PrEP in transgender women in HPTN 083, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings